Alex Therapeutics Reports Results for Almee Under Clinical Evaluation for the Treatment of Anxiety Associated with Pulmonary Fibrosis (PF)
- The (COMPANION) clinical trial evaluated the efficacy of Almee, a 9wk. digital CBT intervention accessed through a smartphone or tablet, in patients (n=108) suffering from anxiety due to PF across the US
- The study met its 1EP of change from baseline in GAD-7 anxiety scores by depicting a 2.7-point improvement vs control thereby demonstrating significant efficacy results in reducing anxiety. Moreover, the study also depicted an improvement in QoL by 4.4 points vs control & in K-BILD psychological domain by 6.5 points
- Almee is an app jointly developed by Alex Therapeutics and its partner Vicore Pharma to offer personalized treatment for anxiety based on cognitive behavioral therapy (CBT)
Ref: Alex Therapeutics | Image: Alex Therapeutics
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at email@example.com
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at firstname.lastname@example.org.